However, use of sorafenib has also been hindered by acquisition of resistance [82]; Gao et al. found that elevated fibroblast growth factor 19 (FGF19) expression or hyper-activation of FGF19/FGFR4 signaling was essential for sorafenib resistance in HCC [83]. Here, FGFR4 is linked to hepatocellular carcinoma.